Please enable JavaScript to continue using this application.

Compare $IVVD vs $LYEL | Chartloom

Compare

$IVVD vs $LYEL

Invivyd Inc · Lyell Immunopharma Inc

IVVD

Invivyd Inc

LYEL

Lyell Immunopharma Inc

Compare $IVVD vs $LYEL

Comparing Invivyd Inc and Lyell Immunopharma Inc

IVVDInvivyd Inc

LYELLyell Immunopharma Inc

IVVDInvivyd Inc

Market cap

$212M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.13x

Rev growth (TTM)

26.3%

YTD performance

-71.2%

52W performance

-56.0%

FCF yield

-51.6%

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IVVD

LYEL

Detailed metrics comparison

IVVD

Invivyd Inc

LYEL

Lyell Immunopharma Inc

Market Cap

IVVD$212M

LYEL$203M

Enterprise Value

IVVD$52M

LYEL$130M

Price

IVVD$0.72

LYEL$8.71

P/E Ratio

IVVDN/A

LYELN/A

P/S Ratio

IVVD3.64x

LYEL7,526.09x

EV/Sales

IVVD0.90x

LYEL4,822.94x

EV/EBITDA

IVVD0.00x

LYEL0.00x

P/B Ratio

IVVD1.34x

LYEL0.97x

P/FCF Ratio

IVVDN/A

LYELN/A

EV/FCF

IVVD-0.48x

LYEL-0.74x

PEG Ratio

IVVDN/A

LYELN/A

Forward P/E (NTM)

IVVDN/A

LYELN/A

Forward P/S (NTM)

IVVD3.13x

LYEL16,911.71x

Revenue (TTM)

IVVD$58M

LYEL$27K

Revenue Growth (YoY)

IVVD26.3%

LYEL-55.0%

Forward Rev Growth

IVVD44.8%

LYEL7184.7%

Gross Margin (TTM)

IVVD92.2%

LYEL0.0%

Operating Margin (TTM)

IVVD0.0%

LYEL0.0%

EBITDA Margin (TTM)

IVVD-191.7%

LYEL-669059.3%

Net Margin (TTM)

IVVD-183.9%

LYEL-920285.2%

FCF Margin (TTM)

IVVD-187.9%

LYEL-648763.0%

Net Income (TTM)

IVVD$-107M

LYEL$-248M

FCF (TTM)

IVVD$-110M

LYEL$-175M

EPS (TTM)

IVVD-$0.33

LYEL-$10.64

ROE (TTM)

IVVD-5973.0%

LYEL-9162.0%

ROA (TTM)

IVVD-4897.0%

LYEL-7050.0%

ROIC (TTM)

IVVD-5973.0%

LYEL-9162.0%

Cash

IVVD$160M

LYEL$73M

Debt

IVVD$0

LYEL$0

Net Cash/Debt

IVVD$160M

LYEL$73M

Current Ratio (TTM)

IVVD5.87x

LYEL5.36x

Quick Ratio (TTM)

IVVD5.60x

LYEL5.12x

Debt/Equity (TTM)

IVVD0.00x

LYEL0.00x

Debt/Assets (TTM)

IVVD0.0%

LYEL0.0%

Interest Coverage (TTM)

IVVDN/A

LYELN/A

Net Debt/EBITDA (TTM)

IVVD0.00x

LYEL0.00x

Beta

IVVD1.32

LYEL-0.04

52W Performance

IVVD-56.0%

LYEL-52.3%

YTD Performance

IVVD-71.2%

LYEL-69.9%

% from 52W High

IVVD-76.5%

LYEL-80.6%

% from 52W Low

IVVD36.7%

LYEL6.1%

Asset Turnover (TTM)

IVVD0.27x

LYEL0.00x

FCF Yield (TTM)

IVVD-51.6%

LYEL-86.2%

Earnings Yield (TTM)

IVVD-50.5%

LYEL-122.3%

Dividend Yield (TTM)

IVVDN/A

LYELN/A

Rule of 40

IVVD-161.6

LYEL-648,818.0

EV/GP/RG

IVVD0.06

LYELN/A

Ticker research

View IVVD research View LYEL research

Metric	IVVD Invivyd Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$212M	$203M
Enterprise Value	$52M	$130M
Price	$0.72	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	3.64x	7,526.09x
EV/Sales	0.90x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.34x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.48x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.13x	16,911.71x
Revenue & Growth
Revenue (TTM)	$58M	$27K
Revenue Growth (YoY)	26.3%	-55.0%
Forward Rev Growth	44.8%	7184.7%
Profitability
Gross Margin (TTM)	92.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-191.7%	-669059.3%
Net Margin (TTM)	-183.9%	-920285.2%
FCF Margin (TTM)	-187.9%	-648763.0%
Net Income (TTM)	$-107M	$-248M
FCF (TTM)	$-110M	$-175M
EPS (TTM)	-$0.33	-$10.64
ROE (TTM)	-5973.0%	-9162.0%
ROA (TTM)	-4897.0%	-7050.0%
ROIC (TTM)	-5973.0%	-9162.0%
Financial Health
Cash	$160M	$73M
Debt	$0	$0
Net Cash/Debt	$160M	$73M
Current Ratio (TTM)	5.87x	5.36x
Quick Ratio (TTM)	5.60x	5.12x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.32	-0.04
52W Performance	-56.0%	-52.3%
YTD Performance	-71.2%	-69.9%
% from 52W High	-76.5%	-80.6%
% from 52W Low	36.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.27x	0.00x
FCF Yield (TTM)	-51.6%	-86.2%
Earnings Yield (TTM)	-50.5%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-161.6	-648,818.0
EV/GP/RG	0.06	N/A
Ticker research	View IVVD research	View LYEL research

Valuation

P/S Ratio

IVVD

3.64x

LYEL

7,526.09x

EV/FCF

LYEL

-0.74x

IVVD

-0.48x

Growth & revenue

Revenue Growth TTM

IVVD

26.3%

LYEL

-55.0%

Forward Revenue Growth

LYEL

7184.7%

IVVD

44.8%

Profitability & performance

Gross Margin

IVVD

92.2%

LYEL

0.0%

ROE

IVVD

-5973.0%

LYEL

-9162.0%

FCF Yield %

IVVD

-51.6%

LYEL

-86.2%

52-Week Performance

LYEL

-52.3%

IVVD

-56.0%

Detailed metrics comparison

IVVD

Invivyd Inc

LYEL

Lyell Immunopharma Inc

Market Cap

IVVD$212M

LYEL$203M

Enterprise Value

IVVD$52M

LYEL$130M

Price

IVVD$0.72

LYEL$8.71

P/E Ratio

IVVDN/A

LYELN/A

P/S Ratio

IVVD3.64x

LYEL7,526.09x

EV/Sales

IVVD0.90x

LYEL4,822.94x

EV/EBITDA

IVVD0.00x

LYEL0.00x

P/B Ratio

IVVD1.34x

LYEL0.97x

P/FCF Ratio

IVVDN/A

LYELN/A

EV/FCF

IVVD-0.48x

LYEL-0.74x

PEG Ratio

IVVDN/A

LYELN/A

Forward P/E (NTM)

IVVDN/A

LYELN/A

Forward P/S (NTM)

IVVD3.13x

LYEL16,911.71x

Revenue (TTM)

IVVD$58M

LYEL$27K

Revenue Growth (YoY)

IVVD26.3%

LYEL-55.0%

Forward Rev Growth

IVVD44.8%

LYEL7184.7%

Gross Margin (TTM)

IVVD92.2%

LYEL0.0%

Operating Margin (TTM)

IVVD0.0%

LYEL0.0%

EBITDA Margin (TTM)

IVVD-191.7%

LYEL-669059.3%

Net Margin (TTM)

IVVD-183.9%

LYEL-920285.2%

FCF Margin (TTM)

IVVD-187.9%

LYEL-648763.0%

Net Income (TTM)

IVVD$-107M

LYEL$-248M

FCF (TTM)

IVVD$-110M

LYEL$-175M

EPS (TTM)

IVVD-$0.33

LYEL-$10.64

ROE (TTM)

IVVD-5973.0%

LYEL-9162.0%

ROA (TTM)

IVVD-4897.0%

LYEL-7050.0%

ROIC (TTM)

IVVD-5973.0%

LYEL-9162.0%

Cash

IVVD$160M

LYEL$73M

Debt

IVVD$0

LYEL$0

Net Cash/Debt

IVVD$160M

LYEL$73M

Current Ratio (TTM)

IVVD5.87x

LYEL5.36x

Quick Ratio (TTM)

IVVD5.60x

LYEL5.12x

Debt/Equity (TTM)

IVVD0.00x

LYEL0.00x

Debt/Assets (TTM)

IVVD0.0%

LYEL0.0%

Interest Coverage (TTM)

IVVDN/A

LYELN/A

Net Debt/EBITDA (TTM)

IVVD0.00x

LYEL0.00x

Beta

IVVD1.32

LYEL-0.04

52W Performance

IVVD-56.0%

LYEL-52.3%

YTD Performance

IVVD-71.2%

LYEL-69.9%

% from 52W High

IVVD-76.5%

LYEL-80.6%

% from 52W Low

IVVD36.7%

LYEL6.1%

Asset Turnover (TTM)

IVVD0.27x

LYEL0.00x

FCF Yield (TTM)

IVVD-51.6%

LYEL-86.2%

Earnings Yield (TTM)

IVVD-50.5%

LYEL-122.3%

Dividend Yield (TTM)

IVVDN/A

LYELN/A

Rule of 40

IVVD-161.6

LYEL-648,818.0

EV/GP/RG

IVVD0.06

LYELN/A

Ticker research

View IVVD research View LYEL research

Metric	IVVD Invivyd Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$212M	$203M
Enterprise Value	$52M	$130M
Price	$0.72	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	3.64x	7,526.09x
EV/Sales	0.90x	4,822.94x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.34x	0.97x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.48x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.13x	16,911.71x
Revenue & Growth
Revenue (TTM)	$58M	$27K
Revenue Growth (YoY)	26.3%	-55.0%
Forward Rev Growth	44.8%	7184.7%
Profitability
Gross Margin (TTM)	92.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-191.7%	-669059.3%
Net Margin (TTM)	-183.9%	-920285.2%
FCF Margin (TTM)	-187.9%	-648763.0%
Net Income (TTM)	$-107M	$-248M
FCF (TTM)	$-110M	$-175M
EPS (TTM)	-$0.33	-$10.64
ROE (TTM)	-5973.0%	-9162.0%
ROA (TTM)	-4897.0%	-7050.0%
ROIC (TTM)	-5973.0%	-9162.0%
Financial Health
Cash	$160M	$73M
Debt	$0	$0
Net Cash/Debt	$160M	$73M
Current Ratio (TTM)	5.87x	5.36x
Quick Ratio (TTM)	5.60x	5.12x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.32	-0.04
52W Performance	-56.0%	-52.3%
YTD Performance	-71.2%	-69.9%
% from 52W High	-76.5%	-80.6%
% from 52W Low	36.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.27x	0.00x
FCF Yield (TTM)	-51.6%	-86.2%
Earnings Yield (TTM)	-50.5%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-161.6	-648,818.0
EV/GP/RG	0.06	N/A
Ticker research	View IVVD research	View LYEL research